BiomEdit, one of Indiana’s newest life-science companies, said Monday it will locate its headquarters in Fishers, but hinted it could eventually move to the new $100 million Elanco Animal Health headquarters campus now under construction in Indianapolis.
Arcane world of pharmacy benefit managers slowly unraveling
A series of federal and state actions are putting the $400 billion PBM industry under a spotlight.Read More
Lilly’s new weight-loss drug is a ‘double wow’ and likely blockbuster
The pharmaceutical giant is turning heads with an experimental medicine it claims can help obese patients shed nearly a quarter of their body weight and manage diabetes.Read More
Indianapolis-based Telix rolls out method for detecting cancer
The imaging agent is the six-year-old company’s first commercial launch, following millions of dollars’ worth of research and clinical tests. It was approved by the U.S. Food and Drug Administration in December.Read More
Financial challenges plague rural hospitals, including in Indiana
Rural hospitals have long struggled to stay afloat. But now, the sector is facing a wave of closings under additional financial pressures, some caused by the pandemic that has strained resources.Read More
This is the third acquisition announced this year for Indianapolis-based Greenlight Guru, which offers a platform to help medical device makers with regulatory requirements.
Several analysts said Elanco faces a bright future, implying that the market might be overreacting to the lowered revenue and profit guidance.
It should come as no surprise that pandemic-related supply chain challenges have also had a major impact on the life sciences industry.
Indiana University Health lost $29.8 million, and Community Health lost $28.5 million during the quarter, as both systems postponed surgeries to deal with the rising number of COVID-19 cases.
The funding included 39 Indiana life-science companies raising $433.5 million last year in venture capital, an increase of almost $200 million compared to 2020, according to a report issued by BioCrossroads.
Acacia Pharma Group employees are waiting to see what will happen to their jobs and whether the company will remain in Indianapolis in any form, now that it is being acquired by New Jersey-based specialty drugmaker Eagle Pharmaceuticals Inc. for $103.9 million.
Brooke Beier, senior vice president of commercialization at the Purdue Research Foundation, said FDA approval of the therapy is one of the most meaningful approvals ever for a Purdue-related innovation.
The West Lafayette life sciences company was awarded the $974,349 grant to further the development of a core technology known as Collymer. It can be used to create implantable materials for tissue restoration and reconstruction needs such as breast tissue, skeletal muscle, cartilage and more.
The medical-device maker is vigorously defending itself against a mountain of lawsuits that claim its inferior vena cava (IVC) filters, designed to catch blood clots, are unsafe.
Tremain has been president of the Indiana Donor Network since 2012, and coaxes people at every opportunity to consider donating their organs after they die to others who need a kidney, liver, heart or other organ.
Indiana’s life-sciences sector, often hailed as a key driver of the state’s economy, landed a record $433 million in venture funding last year, despite the COVID-19 pandemic that challenged so many other sectors, from restaurants to airlines.
Originally intended to divert low-level, nonviolent offenders from criminal justice apparatus, the AIC has assessed 1,700 residents for struggles with mental health or substance abuse disorders.
Not only do you have to rearrange plans to visit customers or attend conferences, but you suddenly need to isolate in a hotel room, find restaurants that deliver, and perhaps reschedule flight and hotel plans.
Central Indiana hospitals diverted ambulances for nearly 3,000 hours during a six-week period this fall, according to information IBJ received from the Indiana State Department of Health through an open-records request.
For the past year, Indiana employers have faced the challenge of whether to enforce COVID-19 vaccination mandates on workers who say the vaccines violate their religious beliefs.